Pharmaceutical Product Monograph: Cefuroxime-Sulbactam Sodium (1.5 g)
In the pharmaceutical industry, Cefuroxime-Sulbactam is a parenteral, fixed-dose combination (FDC) of a Second-Generation Cephalosporin and a Beta-lactamase Inhibitor. As a pharmacist and manufacturer, I view this molecule as an “Enhanced Respiratory and Surgical Agent”—it is technically designed to provide the reliable efficacy of Cefuroxime while using Sulbactam to “neutralize” the defensive enzymes (beta-lactamases) produced by resistant bacteria.
At your WHO-GMP facility in Mumbai, the 1.5 g strength (typically 1 g Cefuroxime + 500 mg Sulbactam) is a flagship SKU for ENT, Respiratory, and Gynecological portfolios. It is a strategic “step-up” for clinicians when standard Cefuroxime monotherapy is failing due to suspected bacterial resistance.
Therapeutic Profile: Primary Indications
Cefuroxime-Sulbactam is indicated for moderate-to-severe infections caused by susceptible organisms, especially those that produce beta-lactamase enzymes.
| Indication | Clinical Context | Technical Rationale |
| Severe RTI | Pneumonia / Bronchitis | Highly effective against H. influenzae and M. catarrhalis that have developed resistance to standard penicillins. |
| ENT Infections | Sinusitis / Otitis Media | Gold Standard: Reaches high concentrations in the middle ear and sinus cavities. |
| OBG Infections | PID / Endometritis | Used to treat pelvic inflammatory disease and post-partum infections involving mixed flora. |
| Surgical Prophylaxis | Pre-operative | Used in abdominal and pelvic surgeries to prevent post-op infections from Gram-positive and Gram-negative aerobes. |
| Skin & Soft Tissue | Cellulitis / Abscesses | Targets Staphylococcus aureus (MSSA) and Streptococcus species in complicated skin infections. |
Mechanism: The “Shield and Sword” Strategy
The combination works through a synergistic biochemical mechanism:
Cefuroxime (The Sword): Like other cephalosporins, it binds to Penicillin-Binding Proteins (PBPs), inhibiting the cross-linking of the bacterial cell wall. This leads to osmotic instability and bacterial lysis.
Sulbactam (The Shield): Many bacteria produce enzymes called Beta-lactamases that “eat” Cefuroxime before it can work. Sulbactam is a “suicide inhibitor” that binds permanently to these enzymes, “sacrificing” itself so that Cefuroxime can reach its target PBP unharmed.
Synergy: Technically, Sulbactam extends the spectrum of Cefuroxime to include many strains of Staphylococci, Klebsiella, and Bacteroides that would otherwise be resistant.
The Pharmacist’s “Technical Warning”
The “Probenecid” Interaction: As a pharmacist, I must warn that taking Probenecid alongside this injection will technically block the renal secretion of Cefuroxime, leading to higher and more prolonged blood levels. This can be used therapeutically but must be monitored.
The “Sequential Therapy” USP: Cefuroxime is unique because it is one of the few antibiotics that can be started as an Injection (IV/IM) and seamlessly continued with the Oral (Cefuroxime Axetil) form once the patient is stable.
Renal Adjustment: While very safe, the dose must be reduced in patients with severe renal impairment ($GFR < 20 \text{ mL/min}$) to avoid accumulation.
Penicillin Cross-Reactivity: About 5–10% of patients with a severe Penicillin allergy may also react to Cefuroxime. Always perform a skin test if the history is unclear.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Dual-Vial” Precision: On your digital marketplace, highlight your Aseptic Co-Filling Technology. Cefuroxime Sodium and Sulbactam Sodium have different physical properties; ensuring a perfectly homogenous 2:1 ratio in every vial is a technical benchmark of your WHO-GMP quality.
The “Respiratory Niche” Advantage: For international B2B tenders, market this combination specifically to Pediatric and ENT specialized clinics. It offers a broader “safety net” than Cefotaxime for community-acquired respiratory infections.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Cefuroxime-Sulbactam 1.5 g to support your registration in international B2B tenders for respiratory and surgical medicine.